NCT03565536

Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer

Completed Phase 2 Last updated 19 April 2024

What this trial tests

Phase 2 trial testing Nexavar in Thyroid Cancer, Anaplastic in 18 participants. Completed in 30 December 2020.

Timeline

1 May 2018

Primary endpoint
30 December 2020

30 December 2020

Quick facts

Lead sponsor	Fujian Medical University
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	18
Start date	1 May 2018
Primary completion	30 December 2020
Estimated completion	30 December 2020
Sites	1 location across China

Drugs / interventions tested

• Nexavar — full drug profile →
• operation
• External radiation therapy

Conditions studied

• Thyroid Cancer, Anaplastic — all drugs for Thyroid Cancer, Anaplastic →

Sponsor

Fujian Medical University

Who can join

18 and older, any sex, with Thyroid Cancer, Anaplastic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Undifferentiated thyroid cancer is the most malignant tumor of the thyroid gland, with a median survival of only 3 months. Most undifferentiated cancers lose the chance of surgery when they are first diagnosed. The current study, Nexavar, is used only for dedifferentiated thyroid cancer and has not been applied to undifferentiated cancer. This study attempted to apply it to preoperative treatment of undifferentiated cancer to see if it would shrink the tumor and give the patient an opportunity for surgery.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Updates on the Management of Thyroid Cancer.
   Araque KA, Gubbi S, Klubo-Gwiezdzinska J. · · 2020 · cited 115× · PMID 32040962 · DOI 10.1055/a-1089-7870
2. Anaplastic Thyroid Carcinoma: An Update.
   Jannin A, Escande A, Al Ghuzlan A, Blanchard P, et al · · 2022 · cited 110× · PMID 35205809 · DOI 10.3390/cancers14041061
3. A Systematic Review of Phase II Targeted Therapy Clinical Trials in Anaplastic Thyroid Cancer.
   Ljubas J, Ovesen T, Rusan M. · · 2019 · cited 33× · PMID 31277524 · DOI 10.3390/cancers11070943
4. Anaplastic Thyroid Cancer: Clinical Picture of the Last Two Decades at a Single Oncology Referral Centre and Novel Therapeutic Options.
   Simões-Pereira J, Capitão R, Limbert E, Leite V. · · 2019 · cited 27× · PMID 31443283 · DOI 10.3390/cancers11081188
5. Molecular features of aggressive thyroid cancer.
   Elia G, Patrizio A, Ragusa F, Paparo SR, et al · · 2022 · cited 26× · PMID 36605433 · DOI 10.3389/fonc.2022.1099280
6. Recent Trends and Potential of Radiotherapy in the Treatment of Anaplastic Thyroid Cancer.
   Sekihara K, Himuro H, Toda S, Saito N, et al · · 2024 · cited 9× · PMID 38927493 · DOI 10.3390/biomedicines12061286
7. Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?
   Gao X, Hong C, Xie Y, Zeng X. · · 2023 · cited 7× · PMID 37007127 · DOI 10.3389/fonc.2023.1103147
8. Leveraging molecular targeted drugs and immune checkpoint inhibitors treat advanced thyroid carcinoma to achieve thyroid carcinoma redifferentiation.
   Su JY, Huang T, Zhang JL, Lu JH, et al · · 2024 · cited 1× · PMID 38455407 · DOI 10.62347/ejaa3388